These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1262 related articles for article (PubMed ID: 16157528)

  • 21. Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.
    Uesaka D; Demura Y; Ishizaki T; Ameshima S; Miyamori I; Sasaki M; Fujibayashi Y; Okazawa H
    J Nucl Med; 2008 Oct; 49(10):1606-12. PubMed ID: 18794269
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
    Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
    J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging in the preoperative staging of head and neck squamous cell carcinoma.
    Roh JL; Yeo NK; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2007 Oct; 43(9):887-93. PubMed ID: 17207656
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective evaluation of CECT and 18F-FDG-PET/CT in detection of hepatic metastases.
    D'souza MM; Sharma R; Mondal A; Jaimini A; Tripathi M; Saw SK; Singh D; Mishra A; Tripathi RP
    Nucl Med Commun; 2009 Feb; 30(2):117-25. PubMed ID: 19057427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 18F-FDG positron emission tomography CT (FDG PET-CT) in the management of pancreatic cancer: initial experience in 12 patients.
    Saif MW; Cornfeld D; Modarresifar H; Ojha B
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):173-8. PubMed ID: 18568138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C; Ceresoli GL; Rizzo G; Artioli D; Cattaneo M; Castellone P; Gregorc V; Picchio M; Landoni C; Fazio F
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
    Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
    Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
    Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of hematogenous bone metastasis in cervical cancer: 18F-fluorodeoxyglucose-positron emission tomography versus computed tomography and magnetic resonance imaging.
    Liu FY; Yen TC; Chen MY; Lai CH; Chang TC; Chou HH; Hong JH; Chen YR; Ng KK
    Cancer; 2009 Dec; 115(23):5470-80. PubMed ID: 19739235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PET/CT detection of unexpected gastrointestinal foci of 18F-FDG uptake: incidence, localization patterns, and clinical significance.
    Israel O; Yefremov N; Bar-Shalom R; Kagana O; Frenkel A; Keidar Z; Fischer D
    J Nucl Med; 2005 May; 46(5):758-62. PubMed ID: 15872347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 18F-FDG PET and PET/CT in Burkitt's lymphoma.
    Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA
    Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):324-8. PubMed ID: 19200683
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
    Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
    Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. (18)F-FDG-PET/CT of orofacial tumors, a value of whole-body imaging approach.
    Ferda J; Ferdová E; Záhlava J; Walter J; Mukensnabl P; Daum O; Kreuzberg B
    Eur J Radiol; 2010 Feb; 73(2):241-8. PubMed ID: 19101104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
    Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
    J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging.
    Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P
    Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer.
    Strobel K; Heinrich S; Bhure U; Soyka J; Veit-Haibach P; Pestalozzi BC; Clavien PA; Hany TF
    J Nucl Med; 2008 Sep; 49(9):1408-13. PubMed ID: 18703604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative risk stratification using (18)F-FDG PET/CT in women with endometrial cancer.
    Lee HJ; Ahn BC; Hong CM; Song BI; Kim HW; Kang S; Jeong SY; Lee SW; Lee J
    Nuklearmedizin; 2011; 50(5):204-13. PubMed ID: 21727990
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lymph node metastasis of squamous cell carcinoma from an unknown primary in the upper and middle neck: Impact of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography.
    Deron PB; Bonte KM; Vermeersch HF; Van de Wiele C
    Cancer Biother Radiopharm; 2011 Jun; 26(3):331-4. PubMed ID: 21711095
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 64.